1Y Close · As of Aug 26, 2026
JW PHARMACEUTICAL operates in the Pharmaceuticals sector.
Legal name: JW PHARMACEUTICAL
In fiscal year 2025, JW PHARMACEUTICAL (001060) reported revenue of 775.3 billion KRW, up 7.8% from 719.4 billion KRW a year earlier.
Operating profit was 94.5 billion KRW and net income was 61.5 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 638.0 billion KRW, with a P/B of 1.73.
These figures can be verified in the DART filing (receipt no. 20260318001544).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 775.3B | 94.5B | 61.5B |
| 2024 | 719.4B | 82.5B | 65.0B |
| 2023 | 748.5B | 100.3B | 38.4B |
| 2022 | 684.4B | 63.0B | 29.9B |
| 2021 | 606.6B | 31.2B | -1.4B |
Recent Filings
Material Business Matters
Semi-Annual Report (2026.06)
Material Business Matters
Checks
1 of 8 checked items currently applicable.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Material Business Matters |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-08-11 | Material Business Matters |
| 2026-08-11 | Fair Trade Compliance Status (Informational Disclosure) |
| 2026-08-11 | Operating (Preliminary) Earnings (Fair Disclosure) |